Research programme: sickle cell anaemia therapeutics - Errant Gene TherapeuticsAlternative Names: Trichosic
Latest Information Update: 15 Jul 2016
At a glance
- Originator Errant Gene Therapeutics
- Class Antibacterials
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Sickle cell anaemia
Most Recent Events
- 15 Jul 2016 Preclinical trials in Sickle cell anaemia in USA (unspecified route)